Chemomab to Present Nebokitug Data at AASLD 2025
Clinical Data Presentation: Chemomab Therapeutics will present new clinical data from the Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC) at the AASLD The Liver Meeting 2025 on November 10, 2025.
Efficacy of Nebokitug: The data from the trial's open label extension shows consistent effects of nebokitug on inflammatory and fibrotic biomarkers, supporting its potential as a disease-modifying treatment for PSC.
Mechanism of Action: Two posters will detail insights into the macrophage-related mechanism of action of nebokitug, which targets the soluble protein CCL24, implicated in fibro-inflammatory diseases like PSC.
Future Studies: The results indicate that nebokitug may slow disease progression and improve clinical outcomes, setting the stage for the upcoming Phase 3 study.
Get Free Real-Time Notifications for Any Stock
Analyst Views on CMMB
About CMMB
About the author
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
